Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Sponsor
Norwegian University of Science and Technology
Study ID
NCT03540420
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    atezolizumab 1200 mg intravenous every 3 weeks in 12 months

Study Details

Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is needed. Immunotherapy represents the largest advance in cancer therapy in recent years and has demonstrated promising activity in SCLC. In this study we will investigate whether atezolizumab prolongs survival in LD SCLC patients who have undergone chemo-radiotherapy.

Key Dates

Start date
Jul 31, 2018
Status verified
Apr 2026
Primary completion
Apr 1, 2024
Completion
Apr 1, 2027

Study Design

Enrollment
212 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab
    atezolizumab after completed chemo-radiotherapy and non-progression
  • No Intervention: Observation
    standard care after completed chemo-radiotherapy and non-progression

Primary Outcome Measure

2 year survival [ Time Frame: 2 year after enrollment is completed ]

Related Studies